<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40353">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112123</url>
  </required_header>
  <id_info>
    <org_study_id>102012-052</org_study_id>
    <secondary_id>1R21AT007869-01</secondary_id>
    <nct_id>NCT02112123</nct_id>
  </id_info>
  <brief_title>Icariin to Prevent Corticosteroid-related Memory Changes</brief_title>
  <official_title>Icariin to Prevent Corticosteroid-related Memory Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Alternative Medicine (NCCAM)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetic properties of icariin, an
      active ingredient in the over-the-counter supplement, Horny Goat Weed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetic properties of icariin, an
      active ingredient in the over-the-counter supplement, Horny Goat Weed.

      Healthy volunteers will be randomly assigned to a 5 day course of icariin at 100 mg/day, 200
      mg/day, 300 mg/day, or 400 mg/day, or a matching placebo.

      24 hours of blood samples will be drawn for pharmacokinetic analysis.  Side effects will be
      assessed for the full 5 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Blood concentration levels of icariin</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>A-SEX</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Arizona Sexual Experiences Scale for measuring side effects relating to sexual functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAFTEE</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Systematic Assessment for Treatment Emergent Events - to assess general side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PT/PTT levels</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Prothrombin time/Partial thromboplastin time</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>the Pharmacokinetic Profile of Icariin in Humans</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo given for 5 days (qd po)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icariin - 100 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Icariin given at 100 mg/day (qd po) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icariin - 200 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Icariin given at 200 mg/day (qd po) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icariin - 300 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Icariin given at 300 mg/day (qd po) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icariin - 400 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Icariin given at 400 mg/day (qd po) for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Icariin</intervention_name>
    <arm_group_label>Icariin - 100 mg/day</arm_group_label>
    <arm_group_label>Icariin - 200 mg/day</arm_group_label>
    <arm_group_label>Icariin - 300 mg/day</arm_group_label>
    <arm_group_label>Icariin - 400 mg/day</arm_group_label>
    <other_name>Horny Goat Weed</other_name>
    <other_name>epimedium extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women

          -  Ages 18 - 50 years

          -  BMI between 18.5 and 30

          -  Ability to read and speak English

        Exclusion Criteria:

          -  Medication changes in the past 30 days

          -  Current or past 30 days opioid therapy

          -  Current or past 30 days erectile dysfunction therapy

          -  Significant medical conditions

          -  History of major psychiatric illness

          -  History of drug/alcohol abuse or current tobacco use

          -  Vulnerable populations including pregnant or nursing women, the incarcerated, or
             individuals with severe cognitive disorders

          -  History of allergic reaction or contraindication to icariin

          -  Baseline QIDS score &gt; 7, current suicidal ideation, or history of suicide attempt

          -  Clinically significant abnormalities on baseline labs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Sherwood Brown, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly K Anderson, BS</last_name>
    <phone>214-645-6954</phone>
    <email>kimberlyk.anderson@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly K Anderson, BS</last_name>
      <phone>214-645-6954</phone>
      <email>kimberlyk.anderson@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>E. Sherwood Brown, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Sherwood Brown</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>icariin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy participants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
